Breaking News

Bioventus Acquires Pfizer’s BMP Portfolio

Expands bone stimulation and injectable therapies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bioventus has entered an agreement with Pfizer for an exclusive, worldwide license to Pfizer’s bone morphogenetic protein (BMP) portfolio of development programs and associated assets. Pfizer received an upfront payment and will be eligible to receive milestone payments and royalties on sales. The portfolio includes a next-generation BMP and the rights to rhBMP-2 in indications and fields previously reserved to Pfizer. Bioventus has also acquired an exclusive option to a BMP program for soft tis...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters